Initially the investigator(s) will focus on imaging breast, pancreas, sarcoma, prostate cancer, bladder cancer, colon cancer, and head and neck cancer.~STUDY AIMS~Determine the dosimetry for gallium-68 labelled (68Ga-) and 64Cu- FAP-2286.~Evaluate the uptake and retention of radiotracer in a variety of solid tumors with FAP-2286.~Evaluate the ability of FAP-2286 to detect metastatic disease.~PRIMARY OBJECTIVES~All cohorts: Safety of 68Ga- and 64Cu-FAP-2286.~Cohort 1a: determine the organ dosimetry of 68Ga-FAP-2286.~Cohort 1b: determine the organ dosimetry of 64Cu-FAP-2286.~Cohort 2: To assess the feasibility of detecting tumor uptake using FAP-2286.~Cohort 3: To determine the feasibility of detecting metastatic disease using FAP-2286.~EXPLORATORY OBJECTIVES~To detect the sensitivity of FAP-2286 PET compared to conventional imaging for the detection of metastatic disease, and when available sensitivity compared to Fluorodeoxyglucose (FDG) PET (FDG-PET).~Correlation of FAP-2286 uptake with FAP expression determined by immunohistochemistry.~Compare biodistribution of 68Ga-FAP-2286 and 64Cu-FAP-2286 in normal organs and blood pool based on renal function.~Determine impact of administered dose of FAP-2286 on image quality.~Compare the feasibility of detecting tumor uptake using 68Ga-FAP-2286 and 64Cu-FAP-2286~A repeat radiolabeled FAP-2286 PET may be obtained after initiation of subsequent treatment in order to evaluate changes in PET uptake due to treatment effect. Patients will be followed for up to 3 days after the injection of radiolabeled ligand for evaluation of adverse events.
This is a multi-arm prospective trial that evaluates the ability of a novel imaging radiolabeled agents to detect metastatic cancer in participants with solid tumors using a gallium 68 (68Ga-) or copper 64 (64Cu-) FAP-2286 tracer. FAP-2286 is a peptidomimetic molecule that that binds to Fibroblast Activation Protein (FAP). FAP is a transmembrane protein expressed on cancer-associated fibroblasts, and has been shown to be present on a number of solid tumors.